Buisson M, Morand P, Genoulaz O, Bourgeat M J, Micoud M, Seigneurin J M
Laboratoire de Virologie, Faculté de Médecine-CHU, Grenoble, France.
J Gen Virol. 1994 Feb;75 ( Pt 2):431-7. doi: 10.1099/0022-1317-75-2-431.
Two types of Epstein-Barr virus (EBV), EBV-1 and EBV-2, were identified on the basis of DNA sequence divergence in the genes for nuclear proteins EBNA 2, 3a, 3b and 3c. In the present study, we conducted an immunological and genomic analysis in a human immunodeficiency virus (HIV)-infected population to determine the prevalence of the two types, and whether the identified type was stable over years. The EBNA-2 serotyping and genotyping showed that HIV-infected patients were highly infected by EBV-2, and that the dominant strain was mostly retained. However, during a follow-up study, a change in the dominant viral strain was observed in two patients. A first HIV-positive patient (patient A), although having a stable level of anti-EBNA-2A and -2B antibodies, showed a change in the genotype and antigen produced in spontaneously established lymphoblastoid cell lines (LCL). The sequence analysis of LCLs confirmed the emergence of the EBV-2 type population. A strain from a second HIV-positive patient (patient B) was clearly identified as EBV-2: the genotype from a saliva sample and from sequential LCLs belonged to EBV-2, as well as the antigen produced from LCLs, and serum antibodies. After a 5-year continuous EBV-2 infection, a reactivation of the EBV-1 strain was observed. In both cases, sequence analysis of the EBNA-2 gene showed, only with EBV-1, the presence of EBV variants related to the B95-8 prototype. Two mutations (at nucleotides 49212 and 49304) were found in both patients A and B, whereas an additional mutation (at nucleotide 49237) was characteristic of the patient A. No mutation relative to the prototype B95-8 strain was observed in a subsequent analysis of this EBNA-2 region from LCLs obtained from two HIV-negative patients predominantly infected by EBV-1. Therefore, we speculate that these mutations may be EBV-1 mutations specifically occurring during HIV infection.
根据核蛋白EBNA 2、3a、3b和3c基因中的DNA序列差异,鉴定出两种类型的爱泼斯坦-巴尔病毒(EBV),即EBV-1和EBV-2。在本研究中,我们对一群感染人类免疫缺陷病毒(HIV)的人群进行了免疫学和基因组分析,以确定这两种类型的流行情况,以及所鉴定的类型在多年间是否稳定。EBNA-2血清分型和基因分型显示,HIV感染患者受EBV-2的感染率很高,且优势毒株大多得以保留。然而,在一项随访研究中,观察到两名患者的优势病毒株发生了变化。第一名HIV阳性患者(患者A),尽管其抗EBNA-2A和-2B抗体水平稳定,但在自发建立的淋巴母细胞系(LCL)中产生的基因型和抗原发生了变化。LCL的序列分析证实了EBV-2型群体的出现。第二名HIV阳性患者(患者B)的一株病毒被明确鉴定为EBV-2:唾液样本和连续LCL的基因型均属于EBV-2,LCL产生的抗原以及血清抗体也属于EBV-2。在持续5年的EBV-2感染后,观察到EBV-1毒株重新激活。在这两个病例中,EBNA-2基因的序列分析表明,仅在EBV-1中存在与B95-8原型相关的EBV变体。在患者A和B中均发现了两个突变(位于核苷酸49212和49304处),而另一个突变(位于核苷酸49237处)是患者A所特有的。在随后对主要感染EBV-1的两名HIV阴性患者的LCL的该EBNA-2区域进行分析时,未观察到相对于原型B95-8毒株的突变。因此,我们推测这些突变可能是HIV感染期间特有的EBV-1突变。